{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T10:35:18Z","timestamp":1782902118092,"version":"3.54.5"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"NINGBO Medical & Health Leading Academic Discipline Project","award":["2022-ZF02"],"award-info":[{"award-number":["2022-ZF02"]}]},{"name":"NINGBO Medical & Health Brand Discipline Project","award":["PPXK2024-08"],"award-info":[{"award-number":["PPXK2024-08"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s11096-024-01778-y","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T12:19:01Z","timestamp":1721737141000},"page":"1381-1390","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Identification of novel signal of proton pump inhibitor-associated drug reaction with eosinophilia and\u00a0systemic symptoms: a disproportionality analysis"],"prefix":"10.1007","volume":"46","author":[{"given":"Wanshu","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3989-0914","authenticated-orcid":false,"given":"Hangjuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,23]]},"reference":[{"issue":"11","key":"1778_CR1","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1001\/jamainternmed.2014.4491","volume":"174","author":"R Dressler","year":"2014","unstructured":"Dressler R, Dryer MM, Coletti C, et al. Altering overuse of cardiac telemetry in non-intensive care unit settings by hardwiring the use of American Heart Association guidelines. JAMA Intern Med. 2014;174(11):1852\u20134. https:\/\/doi.org\/10.1001\/jamainternmed.2014.4491.","journal-title":"JAMA Intern Med"},{"issue":"10","key":"1778_CR2","doi-asserted-by":"publisher","first-page":"738","DOI":"10.17235\/reed.2019.6155\/2019","volume":"111","author":"J Ying","year":"2019","unstructured":"Ying J, Li LC, Wu CY, et al. The status of proton pump inhibitor use: a prescription survey of 45 hospitals in China. Rev Esp Enferm Dig. 2019;111(10):738\u201343. https:\/\/doi.org\/10.17235\/reed.2019.6155\/2019.","journal-title":"Rev Esp Enferm Dig"},{"issue":"5","key":"1778_CR3","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1007\/s12325-017-0532-9","volume":"34","author":"LY Yu","year":"2017","unstructured":"Yu LY, Sun LN, Zhang XH, et al. A review of the novel application and potential adverse effects of proton pump inhibitors. Adv Ther. 2017;34(5):1070\u201386. https:\/\/doi.org\/10.1007\/s12325-017-0532-9.","journal-title":"Adv Ther"},{"issue":"2","key":"1778_CR4","doi-asserted-by":"publisher","first-page":"115","DOI":"10.4068\/cmj.2023.59.2.115","volume":"59","author":"NMP Maideen","year":"2023","unstructured":"Maideen NMP. Adverse effects associated with long-term use of proton pump inhibitors. Chonnam Med J. 2023;59(2):115\u201327. https:\/\/doi.org\/10.4068\/cmj.2023.59.2.115.","journal-title":"Chonnam Med J"},{"issue":"4","key":"1778_CR5","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1053\/j.gastro.2021.12.247","volume":"162","author":"LE Targownik","year":"2022","unstructured":"Targownik LE, Fisher DA, Saini SD. AGA clinical practice update on de-prescribing of proton pump inhibitors: expert review. Gastroenterology. 2022;162(4):1334\u201342.","journal-title":"Gastroenterology"},{"issue":"1","key":"1778_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jamda.2020.09.046","volume":"22","author":"TS Dharmarajan","year":"2021","unstructured":"Dharmarajan TS. The use and misuse of proton pump inhibitors: an opportunity for deprescribing. J Am Med Dir Assoc. 2021;22(1):15\u201322. https:\/\/doi.org\/10.1016\/j.jamda.2020.09.046.","journal-title":"J Am Med Dir Assoc"},{"issue":"11","key":"1778_CR7","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1080\/17512433.2018.1531703","volume":"11","author":"V Savarino","year":"2018","unstructured":"Savarino V, Marabotto E, Zentilin P, et al. Proton pump inhibitors: use and misuse in the clinical setting. Expert Rev Clin Pharmacol. 2018;11(11):1123\u201334. https:\/\/doi.org\/10.1080\/17512433.2018.1531703.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"4","key":"1778_CR8","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1053\/j.gastro.2017.01.031","volume":"152","author":"DE Freedberg","year":"2017","unstructured":"Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology. 2017;152(4):706\u201315. https:\/\/doi.org\/10.1053\/j.gastro.2017.01.031.","journal-title":"Gastroenterology"},{"issue":"5","key":"1778_CR9","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1080\/14740338.2022.2020245","volume":"21","author":"W Song","year":"2022","unstructured":"Song W, Shi L, Wang Y, et al. Proton pump inhibitors and increased reporting odds of renal neoplasms: FAERS-based adverse event data mining and analysis. Expert Opin Drug Saf. 2022;21(5):707\u201313. https:\/\/doi.org\/10.1080\/14740338.2022.2020245.","journal-title":"Expert Opin Drug Saf"},{"key":"1778_CR10","doi-asserted-by":"publisher","first-page":"175628481983451","DOI":"10.1177\/1756284819834511","volume":"12","author":"KS Cheung","year":"2019","unstructured":"Cheung KS, Leung WK. Long-term use of proton-pump inhibitors and risk of gastric cancer: a review of the current evidence. Ther Adv Gastroenterol. 2019;12:1756284819834511. https:\/\/doi.org\/10.1177\/1756284819834511.","journal-title":"Ther Adv Gastroenterol"},{"issue":"9","key":"1778_CR11","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.3390\/ijerph16091571","volume":"16","author":"BKS Thong","year":"2019","unstructured":"Thong BKS, Ima-Nirwana S, Chin KY. Proton pump inhibitors and fracture risk: a review of current evidence and mechanisms involved. Int J Environ Res Public Health. 2019;16(9):1571. https:\/\/doi.org\/10.3390\/ijerph16091571.","journal-title":"Int J Environ Res Public Health"},{"issue":"3","key":"1778_CR12","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/joim.12698","volume":"283","author":"TSG Sehested","year":"2018","unstructured":"Sehested TSG, Gerds TA, Fosbol EL, et al. Long-term use of proton pump inhibitors, dose-response relationship and associated risk of ischemic stroke and myocardial infarction. J Intern Med. 2018;283(3):268\u201381. https:\/\/doi.org\/10.1111\/joim.12698.","journal-title":"J Intern Med"},{"issue":"4","key":"1778_CR13","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1111\/jocd.13763","volume":"20","author":"A Salloum","year":"2021","unstructured":"Salloum A, Nasr D, Maalouf D. Dermatologic adverse reactions to proton-pump inhibitors: a synthetized review. J Cosmet Dermatol. 2021;20(4):1073\u20139. https:\/\/doi.org\/10.1111\/jocd.13763.","journal-title":"J Cosmet Dermatol"},{"issue":"9","key":"1778_CR14","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1515\/jom-2023-0037","volume":"123","author":"M Cho","year":"2023","unstructured":"Cho M, Hostoffer R. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. J Osteopath Med. 2023;123(9):459\u201360. https:\/\/doi.org\/10.1515\/jom-2023-0037.","journal-title":"J Osteopath Med"},{"issue":"18","key":"1778_CR15","doi-asserted-by":"publisher","first-page":"4287","DOI":"10.3390\/jcm10184287","volume":"10","author":"D Jevtic","year":"2021","unstructured":"Jevtic D, Dumic I, Nordin T, et al. Less known gastrointestinal manifestations of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a systematic review of the literature. J Clin Med. 2021;10(18):4287. https:\/\/doi.org\/10.3390\/jcm10184287.","journal-title":"J Clin Med"},{"issue":"5","key":"1778_CR16","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.jaad.2013.01.033","volume":"68","author":"Z Husain","year":"2013","unstructured":"Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: part I. Clinical perspectives. J Am Acad Dermatol. 2013;68(5):693. https:\/\/doi.org\/10.1016\/j.jaad.2013.01.033.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1778_CR17","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/pde.14044","volume":"37","author":"L Metterle","year":"2020","unstructured":"Metterle L, Hatch L, Seminario-Vidal L. Pediatric drug reaction with eosinophilia and systemic symptoms: a systematic review of the literature. Pediatr Dermatol. 2020;37(1):124\u20139. https:\/\/doi.org\/10.1111\/pde.14044.","journal-title":"Pediatr Dermatol"},{"issue":"6","key":"1778_CR18","doi-asserted-by":"publisher","first-page":"489","DOI":"10.2165\/00002018-199921060-00005","volume":"21","author":"SR Knowles","year":"1999","unstructured":"Knowles SR, Shapiro LE, Shear NH. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Saf. 1999;21(6):489\u2013501. https:\/\/doi.org\/10.2165\/00002018-199921060-00005.","journal-title":"Drug Saf"},{"key":"1778_CR19","doi-asserted-by":"publisher","first-page":"104110","DOI":"10.1016\/j.amsu.2022.104110","volume":"79","author":"MA Lafkih","year":"2022","unstructured":"Lafkih MA, Mimouni H, Azizi M, et al. A fatal presentation of DRESS syndrome with multiple visceral failure mimicking septic shock. Ann Med Surg. 2022;79:104110. https:\/\/doi.org\/10.1016\/j.amsu.2022.104110.","journal-title":"Ann Med Surg"},{"issue":"3","key":"1778_CR20","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00228-020-03005-9","volume":"77","author":"S Sharifzadeh","year":"2021","unstructured":"Sharifzadeh S, Mohammadpour AH, Tavanaee A, et al. Antibacterial antibiotic-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a literature review. Eur J Clin Pharmacol. 2021;77(3):275\u201389. https:\/\/doi.org\/10.1007\/s00228-020-03005-9.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"1778_CR21","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.jaip.2022.02.004","volume":"10","author":"N Hama","year":"2022","unstructured":"Hama N, Abe R, Gibson A, et al. Drug-Induced hypersensitivity syndrome (DIHS)\/drug reaction with eosinophilia and systemic symptoms (DRESS): clinical features and pathogenesis. J Allergy Clin Immunol Pract. 2022;10(5):1155-67.e5. https:\/\/doi.org\/10.1016\/j.jaip.2022.02.004.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"1778_CR22","doi-asserted-by":"publisher","first-page":"32","DOI":"10.4103\/idoj.idoj_452_21","volume":"13","author":"R Jindal","year":"2022","unstructured":"Jindal R, Chugh R, Chauhan P, et al. Histopathological characterization of drug rash with eosinophilia and systemic symptoms (DRESS) and comparison with maculopapular drug rash (MPDR). Indian Dermatol Online J. 2022;13(1):32\u20139. https:\/\/doi.org\/10.4103\/idoj.idoj_452_21.","journal-title":"Indian Dermatol Online J"},{"issue":"2","key":"1778_CR23","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.therap.2023.09.011","volume":"79","author":"T Bettuzzi","year":"2024","unstructured":"Bettuzzi T, Sanchez-Pena P, Lebrun-Vignes B. Cutaneous adverse drug reactions. Therapie. 2024;79(2):239\u201370. https:\/\/doi.org\/10.1016\/j.therap.2023.09.011.","journal-title":"Therapie"},{"issue":"2","key":"1778_CR24","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.2500\/aap.2020.41.190033","volume":"41","author":"S Kepil Ozdemir","year":"2020","unstructured":"Kepil Ozdemir S, Bavbek S. Hypersensitivity reactions to proton-pump inhibitors: clinical presentation, diagnosis, and management. Allergy Asthma Proc. 2020;41(2):e37\u201344. https:\/\/doi.org\/10.2500\/aap.2020.41.190033.","journal-title":"Allergy Asthma Proc"},{"key":"1778_CR25","doi-asserted-by":"publisher","first-page":"107832","DOI":"10.1016\/j.yebeh.2021.107832","volume":"117","author":"BK Kamitaki","year":"2021","unstructured":"Kamitaki BK, Minacapelli CD, Zhang P, et al. Drug-induced liver injury associated with antiseizure medications from the FDA Adverse Event Reporting System (FAERS). Epilepsy Behav. 2021;117:107832. https:\/\/doi.org\/10.1016\/j.yebeh.2021.107832.","journal-title":"Epilepsy Behav"},{"issue":"2","key":"1778_CR26","first-page":"15","volume":"5","author":"M Ismail","year":"2022","unstructured":"Ismail M, Akram MU. FDA adverse event reporting system (FAERS) database: a comprehensive analysis of its structure, functionality, and limitations. Sage Sci Rev Appl Mach Learn. 2022;5(2):15\u201329.","journal-title":"Sage Sci Rev Appl Mach Learn"},{"issue":"2","key":"1778_CR27","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1007\/s11096-023-01678-7","volume":"46","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Jiang H, Xue L, et al. Exploring the safety profile of tremelimumab: an analysis of the FDA adverse event reporting system. Int J Clin Pharm. 2024;46(2):480\u20137. https:\/\/doi.org\/10.1007\/s11096-023-01678-7.","journal-title":"Int J Clin Pharm"},{"issue":"2","key":"1778_CR28","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s11096-023-01676-9","volume":"46","author":"S Zhang","year":"2024","unstructured":"Zhang S, Wang Y, Qi Z, et al. Data mining and analysis of adverse event signals associated with teprotumumab using the Food and Drug Administration adverse event reporting system database. Int J Clin Pharm. 2024;46(2):471\u20139. https:\/\/doi.org\/10.1007\/s11096-023-01676-9.","journal-title":"Int J Clin Pharm"},{"key":"1778_CR29","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1080\/14740338.2023.2204227","volume":"23","author":"P An","year":"2023","unstructured":"An P, Liu X, Zhang B. Safety profile of clobazam in the real world: an analysis of FAERS database and systematic review of case reports. Expert Opin Drug Saf. 2023;23:119\u201328. https:\/\/doi.org\/10.1080\/14740338.2023.2204227.","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"1778_CR30","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/all.13235","volume":"73","author":"CY Lin","year":"2018","unstructured":"Lin CY, Wang CW, Hui CR, et al. Delayed-type hypersensitivity reactions induced by proton pump inhibitors: a clinical and in vitro T-cell reactivity study. Allergy. 2018;73(1):221\u20139. https:\/\/doi.org\/10.1111\/all.13235.","journal-title":"Allergy"},{"issue":"3","key":"1778_CR31","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/bjd.12125","volume":"168","author":"A Barbaud","year":"2013","unstructured":"Barbaud A, Collet E, Milpied B, et al. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions. Br J Dermatol. 2013;168(3):555\u201362. https:\/\/doi.org\/10.1111\/bjd.12125.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1778_CR32","doi-asserted-by":"publisher","first-page":"407","DOI":"10.4103\/0378-6323.158636","volume":"81","author":"A Za\u00efem","year":"2015","unstructured":"Za\u00efem A, Charfi O, Badri T, et al. Fatal outcome of DRESS syndrome associated with esomeprazole. Indian J Dermatol Venereol Leprol. 2015;81(4):407\u20138. https:\/\/doi.org\/10.4103\/0378-6323.158636.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"11","key":"1778_CR33","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1111\/j.1398-9995.2007.01428.x","volume":"62","author":"S Caboni","year":"2007","unstructured":"Caboni S, Gunera-Saad N, Ktiouet-Abassi S, et al. Esomeprazole-induced DRESS syndrome. Studies of cross-reactivity among proton-pump inhibitor drugs. Allergy. 2007;62(11):1342\u20133. https:\/\/doi.org\/10.1111\/j.1398-9995.2007.01428.x.","journal-title":"Allergy"},{"issue":"42","key":"1778_CR34","doi-asserted-by":"publisher","first-page":"e22509","DOI":"10.1097\/MD.0000000000022509","volume":"99","author":"Q He","year":"2020","unstructured":"He Q, Ying G, Fei X, et al. Drug rash with eosinophilia and systemic symptoms and severe renal injury induced by proton pump inhibitor therapy: a case report. Medicine. 2020;99(42):e22509. https:\/\/doi.org\/10.1097\/MD.0000000000022509.","journal-title":"Medicine"},{"issue":"3","key":"1778_CR35","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1684\/ejd.2014.2343","volume":"24","author":"D Bourneau-Martin","year":"2014","unstructured":"Bourneau-Martin D, Leclech C, Jamet A, et al. Omeprazole-induced drug reaction with eosinophilia and systemic symptoms (DRESS). Eur J Dermatol. 2014;24(3):413\u20135. https:\/\/doi.org\/10.1684\/ejd.2014.2343.","journal-title":"Eur J Dermatol"},{"issue":"1","key":"1778_CR36","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HG, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3\u201310. https:\/\/doi.org\/10.1002\/pds.668.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"1778_CR37","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10(6):483\u20136. https:\/\/doi.org\/10.1002\/pds.677.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"1778_CR38","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1111\/bjd.12501","volume":"169","author":"SH Kardaun","year":"2013","unstructured":"Kardaun SH, Sekula P, Valeyrie-Allanore L, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013;169(5):1071\u2013780. https:\/\/doi.org\/10.1111\/bjd.12501.","journal-title":"Br J Dermatol"},{"issue":"8","key":"1778_CR39","doi-asserted-by":"publisher","first-page":"3208","DOI":"10.1016\/j.jaip.2021.05.008","volume":"9","author":"SB Bluestein","year":"2021","unstructured":"Bluestein SB, Yu R, Stone C Jr, et al. Reporting of drug reaction with eosinophilia and systemic symptoms from 2002 to 2019 in the US Food and Drug Administration Adverse Event Reporting System. J Allergy Clin Immunol Pract. 2021;9(8):3208-11.e1. https:\/\/doi.org\/10.1016\/j.jaip.2021.05.008.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"1778_CR40","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7241\/ourd.20233.6","volume":"14","author":"Z Mehsas","year":"2023","unstructured":"Mehsas Z, Boubnane I, Sektaoui S, et al. DRESS syndrome: a descriptive series of 62 cases. Our Dermatol Online. 2023;14(3):268\u201373.","journal-title":"Our Dermatol Online"},{"issue":"2","key":"1778_CR41","doi-asserted-by":"publisher","first-page":"168","DOI":"10.2174\/1574884715666200628113508","volume":"16","author":"R Neha","year":"2021","unstructured":"Neha R, Beulah E, Anusha B, et al. Vemurafenib induced drug reaction with eosinophilia and systemic symptoms (DRESS): a disproportionality analysis in FAERS database. Curr Rev Clin Exp Pharmacol. 2021;16(2):168\u201373. https:\/\/doi.org\/10.2174\/1574884715666200628113508.","journal-title":"Curr Rev Clin Exp Pharmacol"},{"issue":"1","key":"1778_CR42","doi-asserted-by":"publisher","first-page":"30","DOI":"10.4103\/ijd.IJD_582_17","volume":"63","author":"A De","year":"2018","unstructured":"De A, Rajagopalan M, Sarda A, et al. Drug reaction with eosinophilia and systemic symptoms: an update and review of recent literature. Indian J Dermatol. 2018;63(1):30\u201340. https:\/\/doi.org\/10.4103\/ijd.IJD_582_17.","journal-title":"Indian J Dermatol"},{"issue":"3","key":"1778_CR43","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11882-016-0595-8","volume":"16","author":"IM Otani","year":"2016","unstructured":"Otani IM, Banerji A. Immediate and delayed hypersensitivity reactions to proton pump inhibitors: evaluation and management. Curr Allergy Asthma Rep. 2016;16(3):17. https:\/\/doi.org\/10.1007\/s11882-016-0595-8.","journal-title":"Curr Allergy Asthma Rep"},{"issue":"3","key":"1778_CR44","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.iac.2009.04.007","volume":"29","author":"Y Kano","year":"2009","unstructured":"Kano Y, Shiohara T. The variable clinical picture of drug-induced hypersensitivity syndrome\/drug rash with eosinophilia and systemic symptoms in relation to the eliciting drug. Immunol Allergy Clin N Am. 2009;29(3):481\u2013501. https:\/\/doi.org\/10.1016\/j.iac.2009.04.007.","journal-title":"Immunol Allergy Clin N Am"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-024-01778-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-024-01778-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-024-01778-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T02:08:30Z","timestamp":1732068510000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-024-01778-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,23]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1778"],"URL":"https:\/\/doi.org\/10.1007\/s11096-024-01778-y","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,23]]},"assertion":[{"value":"22 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have not disclosed any competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}